Prihlásiť sa Zaregistrujte sa zadarmo

EBITDA spoločnosti QSAM Biosciences

Aká je hodnota metriky EBITDA spoločnosti QSAM Biosciences?

Hodnota metriky EBITDA spoločnosti QSAM Biosciences, Inc. je -$1.30

Aká je definícia metriky EBITDA?



EBITDA je zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie reprezentujúci operačnú výkonnosť spoločnosti.

Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.

EBITDA spoločností v sektore Health Care sektor na OTC v porovnaní so spoločnosťou QSAM Biosciences

Čomu sa venuje spoločnosť QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Firmy s metrikou ebitda podobnou spoločnosti QSAM Biosciences